

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10511314	
	Filing Date		2005-05-17	
	First Named Inventor	David WALLACH		
	Art Unit	1652		
	Examiner Name	S. Swope		
Attorney Docket Number		WALLACH33		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5854003		1998-12-29	Rothe et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	9737016	WO	A1	1997-10-09	Wallach et al.		<input type="checkbox"/>
	2	0 578 932	EP	A2	1994-01-19	Sugamura et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS							Remove
---------------------------------	--	--	--	--	--	--	--------

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10511314	10511314 - GAU: 1652
Filing Date	2005-05-17	
First Named Inventor	David WALLACH	
Art Unit	1652	
Examiner Name	S. Swope	
Attorney Docket Number	WALLACH33	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Rothe et al., "A Novel Family of Putative Signal Transducers Associated with the Cytoplasmic Domain of the 75 kDa Tumor Necrosis Factor Receptor" Cell, 78: 681-692 (1994)	<input type="checkbox"/>
	2	Smith., "Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion Surface" Science, 228:1315-17 (1984)	<input type="checkbox"/>
	3	Fields et al., "A novel genetic system to detect protein-protein interactions" Nature, 340: 265-6 (1989)	<input type="checkbox"/>
	4	Akiba et al., "CD27, a Member of the Tumor Necrosis Factor Receptor Superfamily, Activates NF-kB and Stress-activated Protein Kinase/c-Jun N-terminal Kinase via TRAF2, TRAF5, and NF-kB-inducing Kinase" J. Biol Chem, 273 (21): 13353-13358 (1998)	<input type="checkbox"/>
	5	Baldwin, Jr., "The NF-kB and IkB Proteins: New Discoveries and Insights" Annu. Rev. Immunol, 14: 649-83 (1996)	<input type="checkbox"/>
	6	Ghosh et al., "NF-kB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses" Annu. Rev. Immunol, 16:225-60 (1998)	<input type="checkbox"/>
	7	Karin et al., "PHOSPHORYLATION MEETS UBIQUITINATION: The Control of NF-kB Activity" Ann. Rev. Immunol, 18:621-663 (2000)	<input type="checkbox"/>
	8	Canicio et al., "Nuclear Factor kB-inducing Kinase and IkB Kinase-a Signal Skeletal Muscle Cell Differentiation" J Biol Chem, 276(23): 20228-33 (2001)	<input type="checkbox"/>
	9	Darnay et al., "Activation of NF-kB by RANK Requires Tumor Necrosis Factor Receptor-associated Factor (TRAF) 6 and NF-kB-inducing Kinase" J Biol Chem, 274, 12:7724-31 (1999)	<input type="checkbox"/>
	10	DiSanto et al., "Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain", Proc. Natl. Acad. Sci., 92:377-381 (1995)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10511314	10511314 - GAU: 1652
Filing Date	2005-05-17	
First Named Inventor	David WALLACH	
Art Unit	1652	
Examiner Name	S. Swope	
Attorney Docket Number	WALLACH33	

11	Fagarasan et al., "Allymphoplasia (aly)-type Nuclear Factor $\kappa$ B-inducing (NIK) Kinase Causes Defects in Secondary Lymphoid Tissue Chemokine Receptor Signaling and Homing of Peritoneal Cells to the Gut-associated Lymphatic Tissue System", J. Exp. Med., Vol. 191, 1477-86 (2000)	<input type="checkbox"/>
12	Foehr et al., "The NF- $\kappa$ B-inducing Kinase Induces PC12 Cell Differentiation and Prevents Apoptosis", J Biol Chem, Vol. 275 (44): 34021-24 (2000)	<input type="checkbox"/>
13	Matsushima et al., "Essential Role of Nuclear Factor (NF)- $\kappa$ B-inducing Kinase and Inhibitor of $\kappa$ B (I $\kappa$ B) Kinase $\alpha$ in NF $\kappa$ B Activation through Lymphotoxin $\beta$ Receptor, but Not through Tumor Necrosis Factor Receptor 1", J. Exp. Med. Volume 193, 5:631-636 (2001)	<input type="checkbox"/>
14	Mercurio et al., "Multiple signals converging on NF- $\kappa$ B", Current Opinion in Cell Biology, 11:226-232 (1999)	<input type="checkbox"/>
15	Natoli et al., "Tumor Necrosis Factor (TNF) Receptor 1 Signaling Downstream of TNF Receptor-associated Factor 2: NUCLEAR FACTOR $\kappa$ B (NF $\kappa$ B)-INDUCING KINASE REQUIREMENT FOR ACTIVATION OF ACTIVATING PROTEIN 1 AND NF $\kappa$ B BUT NOT OF c-Jun N-TERMINAL KINASE/STRESS-ACTIVATED PROTEIN KINASE" J Biol Chem, Vol. 272(42):26079-26082 (1997)	<input type="checkbox"/>
16	Pahl et al., "Activators and target genes of Rel/NF- $\kappa$ B transcription factors" Oncogene, Vol 18: 6853-6866 (1999)	<input type="checkbox"/>
17	Regnier et al., "Identification and Characterization of an I $\kappa$ B Kinase" Cell, Vol. 90:373-383 (1997)	<input type="checkbox"/>
18	Noguchi et al., "Interleukin-2 Receptor $\gamma$ Chain Mutation Results in X-Linked Severe Combined Immunodeficiency in Humans" Cell, Vol. 73: 147-157 (1993)	<input type="checkbox"/>
19	Senftleben et al., "Activation by IKK $\alpha$ of a Second, Evolutionary Conserved, NF- $\kappa$ B Signaling Pathway" Science, Vol. 293:1495-9 (2001)	<input type="checkbox"/>
20	Shinkura et al., "Allymphoplasia is caused by a point mutation in the mouse gene encoding NF- $\kappa$ B-inducing kinase" Nat Genet, Vol. 22:74-7 (1999)	<input type="checkbox"/>
21	Sylla et al., "Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF- $\kappa$ B through a pathway that includes the NF- $\kappa$ B-inducing kinase and the I $\kappa$ B kinases IKK $\alpha$ and IKK $\beta$ " Proc. Natl. Acad. Sci. Vol. 95:10106-10111 (1998)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10511314	10511314 - GAU: 1652
Filing Date	2005-05-17	
First Named Inventor	David WALLACH	
Art Unit	1652	
Examiner Name	S. Swope	
Attorney Docket Number	WALLACH33	

22	Takeuchi et al., "Anatomy of TRAF2: DISTINCT DOMAINS FOR NUCLEAR FACTOR-kB ACTIVATION AND ASSOCIATION WITH TUMOR NECROSIS FACTOR SIGNALING PROTEINS" J Biol Chem, Vol. 271(33): 19935-42 (1996)	<input type="checkbox"/>
23	Uhlik et al., "NF-kB-inducing Kinase and Ikb Kinase Participate in Human T-cell Leukemia Virus I Tax-mediated NF-kB Activation" J Biol Chem, Vol. 273(33): 21132-21136 (1998)	<input type="checkbox"/>
24	Xiao et al., "Negative Regulation of the Nuclear Factor kB-inducing Kinase by a cis-Acting Domain" J Biol Chem, Vol. 275(28): 21081-21085 (2000)	<input type="checkbox"/>
25	Xiao et al., "NF-kB-Inducing Kinase Regulates the Processing of NF-kB2 p100" Molecular Cell, Vol. 7:401-409 (2001)	<input type="checkbox"/>
26	Yamada et al., "Abnormal Immune Function of Hemopoietic Cells from Alymphoplasia (aly) Mice, a Natural Strain with Mutant NF-kB-Inducing Kina" J. Immunol, 165: 804-812 (2000)	<input type="checkbox"/>
27	Yamamoto et al., "Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer" The Journal of Clinical Investigation, Vol. 107(2): 135-142 (2001)	<input type="checkbox"/>
28	Yin et al., "Defective Lymphotoxin-b Receptor Induced NF-kB Transcriptional Activity in NIK-Deficient Mice" Science, Vol 291:2162-2165 (2001)	<input type="checkbox"/>
29	Leonard et al., "Role of the Common Cytokine Receptor (gamma)Chain in Cytokine Signaling and Lymphoid Development" Immunol Rev, No. 148: 97-114 1995 SLS 4/15/09	<input type="checkbox"/>
30	Adang et al., "The Contribution of Combinatorial Chemistry to Lead Generation: An Interim Analysis" Curr Med Chem, 8:985-998 (2001)	<input type="checkbox"/>
31	Miyawaki et al., "A new mutation, aly, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice" Eur. J. Immunol, Vol. 24: 429-434 (1994)	<input type="checkbox"/>
32	Garceau et al., "Lineage-restricted function of nuclear factor kappaB-inducing kinase (NIK) in transducing signals via CD40" J. Exp Med, Vol. 191:381-6. (2000)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number	10511314	10511314 - GAU: 1652
Filing Date	2005-05-17	
First Named Inventor	David WALLACH	
Art Unit	1652	
Examiner Name	S. Swope	
Attorney Docket Number	WALLACH33	

33	Gelezianus et al., "Human T-cell leukemia virus type 1 Tax induction of NF-kappaB involves activation of the IkappaB kinase alpha (IKKalpha) and IKKbeta cellular kinases" Mol Cell Biol, Vol. 18: 5157-65. (1998).	<input type="checkbox"/>
34	Lin et al., "The protooncogene Cot kinase participates in CD3/CD28 induction of NF-kappaB acting through the NF-kappaB-inducing kinase and IkappaB kinases" Immunity, Vol 10:271-80 (1999)	<input type="checkbox"/>
35	Ling et al., "NF-kappaB-inducing kinase activates IKK-alpha 15 by phosphorylation of Ser-176" Proc Natl Acad Sci, Vol 95:3792-7. (1998)	<input type="checkbox"/>
36	Malinin et al., "MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1" Nature, 385:540-4. (1997)	<input type="checkbox"/>
37	Matsumoto et al., "Involvement of distinct cellular 20 compartments in the abnormal lymphoid organogenesis in lymphotoxin-alpha-deficient mice and alymphoplasia (aly) mice defined by the chimeric analysis" J. Immunol, 163, 1584-91 (1999)	<input type="checkbox"/>
38	Rothe et al., "Human NIK protein" DATABASE GENESEQ 'Online! EBI, Hinxton, Cambridgeshire, U.K. Database accession no. AAW62497 (1999-03-04)	<input type="checkbox"/>
39	Boldin et al., "Amino acid sequence of NF-kappaB inducing kinase" DATABASE GENESEQ 'Online! EBI, Hinxton, Cambridgeshire, U.K.; Database accession no. AAW42402 (1998-04-15)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Sheridan Swope/	Date Considered	04/15/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.